The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a block of recommendations this month, endorsing several new marketing authorisations and reaffirming prior regulators’ decisions. The committee backed medicines from multiple sponsors, including Hansoh and Cytokinetics, and recommended approvals that align with recent U.S. and U.K. authorizations in select indications. Among the positive rulings, CHMP recommended Anktiva (nogapendekin alfa inbakicept‑pmin) for non‑muscle invasive bladder cancer after BCG failure and supported Cytokinetics’ Myqorzo for obstructive hypertrophic cardiomyopathy. The decisions clear key regulatory hurdles ahead of formal European Commission adoption and will influence market access planning across the region.